PTC Therapeutics, Inc. (PTCT): Price and Financial Metrics
GET POWR RATINGS... FREE!
PTCT POWR Grades
- PTCT scores best on the Value dimension, with a Value rank ahead of 81.68% of US stocks.
- PTCT's strongest trending metric is Growth; it's been moving up over the last 179 days.
- PTCT ranks lowest in Sentiment; there it ranks in the 3rd percentile.
PTCT Stock Summary
- Ptc Therapeutics Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than 99.88% of US listed stocks.
- Of note is the ratio of Ptc Therapeutics Inc's sales and general administrative expense to its total operating expenses; merely 15.17% of US stocks have a lower such ratio.
- PTCT's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of 96.27% of US stocks.
- Stocks with similar financial metrics, market capitalization, and price volatility to Ptc Therapeutics Inc are PLX, POLY, CCLP, TEN, and CROX.
- Visit PTCT's SEC page to see the company's official filings. To visit the company's web site, go to www.ptcbio.com.
PTCT Valuation Summary
- PTCT's EV/EBIT ratio is -12.8; this is 143.69% lower than that of the median Healthcare stock.
- PTCT's price/earnings ratio has moved down 10.6 over the prior 100 months.
- PTCT's EV/EBIT ratio has moved down 15.2 over the prior 100 months.
Below are key valuation metrics over time for PTCT.
Stock | Date | P/S | P/B | P/E | EV/EBIT |
---|---|---|---|---|---|
PTCT | 2021-08-31 | 6.5 | 15.7 | -7.9 | -12.8 |
PTCT | 2021-08-30 | 6.3 | 15.1 | -7.6 | -12.4 |
PTCT | 2021-08-27 | 6.3 | 15.2 | -7.6 | -12.5 |
PTCT | 2021-08-26 | 6.0 | 14.4 | -7.3 | -11.9 |
PTCT | 2021-08-25 | 6.1 | 14.6 | -7.3 | -12.0 |
PTCT | 2021-08-24 | 6.0 | 14.4 | -7.2 | -11.9 |
PTCT Growth Metrics
- Its 5 year cash and equivalents growth rate is now at 206.95%.
- Its 2 year cash and equivalents growth rate is now at 26.22%.
- Its 3 year net income to common stockholders growth rate is now at -4.12%.

The table below shows PTCT's growth in key financial areas (numbers in millions of US dollars).
Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
---|---|---|---|
2021-12-31 | 538.593 | -251.332 | -523.901 |
2021-09-30 | 492.225 | -246.858 | -454.99 |
2021-06-30 | 471.886 | -169.009 | -391.058 |
2021-03-31 | 430.449 | -212.674 | -454.115 |
2020-12-31 | 380.766 | -194.071 | -438.16 |
2020-09-30 | 358.361 | -139.911 | -441.483 |
PTCT's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- PTCT has a Quality Grade of C, ranking ahead of 45.84% of graded US stocks.
- PTCT's asset turnover comes in at 0.235 -- ranking 183rd of 682 Pharmaceutical Products stocks.
- NMTR, ZIOP, and ATXS are the stocks whose asset turnover ratios are most correlated with PTCT.
The table below shows PTCT's key quality metrics over time.
Period | Asset Turnover | Gross Margin | ROIC |
---|---|---|---|
2021-09-30 | 0.235 | 0.943 | -0.271 |
2021-06-30 | 0.221 | 0.945 | -0.205 |
2021-03-31 | 0.216 | 0.944 | -0.305 |
2020-12-31 | 0.205 | 0.950 | -0.360 |
2020-09-30 | 0.210 | 0.951 | -0.473 |
2020-06-30 | 0.198 | 0.949 | -0.648 |
PTCT Price Target
For more insight on analysts targets of PTCT, see our PTCT price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
Average Price Target | $61.58 | Average Broker Recommendation | 1.77 (Moderate Buy) |
PTCT Stock Price Chart Interactive Chart >
PTCT Price/Volume Stats
Current price | $30.58 | 52-week high | $45.80 |
Prev. close | $31.36 | 52-week low | $29.94 |
Day low | $29.94 | Volume | 540,000 |
Day high | $31.60 | Avg. volume | 666,941 |
50-day MA | $37.26 | Dividend yield | N/A |
200-day MA | $38.62 | Market Cap | 2.18B |
PTC Therapeutics, Inc. (PTCT) Company Bio
PTC Therapeutics is a global biopharmaceutical company focused on the discovery, development and commercialization of orally administered, proprietary small molecule drugs targeting an area of RNA biology we refer to as post-transcriptional control. The company was founded in 1998 and is based in South Plainfield, New Jersey.
Latest PTCT News From Around the Web
Below are the latest news stories about Ptc Therapeutics Inc that investors may wish to consider to help them evaluate PTCT as an investment opportunity.
PTC Therapeutics, Inc. (PTCT) CEO Stuart Peltz on Q4 2021 Results - Earnings Call TranscriptPTC Therapeutics, Inc. (PTCT) Q4 2021 Earnings Conference Call February 22, 2022, 16:30 ET Company Participants Kylie O'Keefe - VP, Head of Global Strategic Marketing & Business Intelligence Stuart Peltz - Co-Founder & CEO Matthew Klein - COO Eric Pauwels - Chief Business Officer Emily Hill - CFO Conference Call... |
PTC Therapeutics to Participate at Upcoming Investor ConferencesPTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company update at the following conferences: |
PTC Therapeutics Provides a Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial ResultsSOUTH PLAINFIELD, N.J., Feb. 22, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and financial results for the fourth quarter and full year ending December 31, 2021. "It is gratifying to see that after two years of investment in the innovation |
PTC Therapeutics GAAP EPS of -$2.03 misses by $0.34, revenue of $165.2M beats by $4.12MPTC Therapeutics press release (NASDAQ:PTCT): Q4 GAAP EPS of -$2.03 misses by $0.34.Revenue of $165.2M (+39.0% Y/Y) beats by $4.12M. |
PTC Therapeutics (PTCT) Reports Q4 Loss, Tops Revenue EstimatesPTC Therapeutics (PTCT) delivered earnings and revenue surprises of -13.41% and 1.78%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock? |
PTCT Price Returns
1-mo | -23.84% |
3-mo | -15.13% |
6-mo | -19.65% |
1-year | -22.88% |
3-year | -22.52% |
5-year | 142.89% |
YTD | -23.22% |
2021 | -34.74% |
2020 | 27.07% |
2019 | 39.95% |
2018 | 105.76% |
2017 | 52.89% |
Continue Researching PTCT
Want to do more research on Ptc Therapeutics Inc's stock and its price? Try the links below:Ptc Therapeutics Inc (PTCT) Stock Price | Nasdaq
Ptc Therapeutics Inc (PTCT) Stock Quote, History and News - Yahoo Finance
Ptc Therapeutics Inc (PTCT) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...